NCT05178862: An ongoing trial by Scynexis, Inc.
This trial is ongoing. It must report results 5 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05178862 |
|---|---|
| Title | A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin Followed by Oral Ibrexafungerp Versus Intravenous Echinocandin Followed by Oral Fluconazole (MARIO) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 3, 2022 |
| Completion date | Nov. 7, 2025 |
| Required reporting date | Nov. 7, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 3, 2026 |
| Days late | None |